Bladder-sparing treatment for HER2-positive muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two medications, disitamab vedotin and toripalimab, to treat bladder cancer that has grown into the muscle layer of the bladder. The goal is to see if this treatment can save the bladder while effectively fighting the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your bladder cancer has grown into the muscle layer (muscle-invasive) and has not spread beyond the bladder.
- Your cancer cells show a specific marker called HER2 (at least a 1+ result).
- You have not had chemotherapy or other systemic treatments for bladder cancer before.
- You are generally well enough to perform daily activities (ECOG score 0 or 1).
- Your vital organs like heart, bone marrow, liver, and kidneys are functioning adequately.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—vedisertib (RC48) and toripalimab—for people with bladder cancer that has invaded the muscle but hasn't spread. The goal is to preserve the bladder while treating the cancer.
This trial tests a combination of a targeted drug (disitamab vedotin) and an immunotherapy (toripalimab) before surgery for bladder cancer that has grown into the muscle. The goal is to see if this combination works better than the standard chemotherapy plus immunotherapy approach.
This study tests a combination of two drugs (toripalimab and RC48-ADC) plus radiation therapy to treat bladder cancer while keeping the bladder intact. It aims to see if this approach can control the cancer without needing to remove the bladder.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
This trial tests a combination of an antibody-drug conjugate (RC48) plus chemotherapy (gemcitabine) given before bladder removal surgery. It is for people with HER2-positive bladder cancer that has grown into the muscle layer.
Hear when a new Urology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.